About 360 MG Mycophenolic Acid Delayed-Release Tablets USP
Capitalise on the ineffable efficacy of MOFOCON-S 360, exquisitely crafted by Concord Biotech. Tailored for first-string renal transplant patients, these special 360 MG Mycophenolic Acid Delayed-Release Tablets USP personalise immunosuppression, safeguarding against organ rejection. Presented in pristine white, non-chewable tablets within secure blister packs, each strip contains 10 doses with a shelf life of 24 months. With its delayed-release technology and prescription-only status, MOFOCON-S 360 demonstrates superior precision and control for adult users, ensuring optimal treatment outcomes. Manufactured, marketed, and exported in India, it guarantees both quality and reliability.
Targeted Immunosuppressant Support for Renal Transplant Patients
MOFOCON-S 360 is used as a potent immunosuppressant, specifically designed to prevent organ rejection in renal transplant recipients. The delayed-release formulation guarantees targeted application in the gastrointestinal tract, enhancing efficacy and patient comfort. Its usage is strictly for adults as prescribed by a physician, maintaining strict adherence to individualised therapy protocols for best outcomes. MOFOCON-S 360's advanced delivery system ensures precise, controlled release of Mycophenolic Acid for superior transplant management.
Global Availability and Unmatched Market Value for Exporters
With a reliable FOB port in India, MOFOCON-S 360 delivers high market value by reaching main export markets worldwide. The robust supply ability meets diverse demands, ensuring consistent availability for traders and suppliers. Each shipment, carefully packaged for stability, guarantees that freight distribution maintains the tablets' integrity. Concord Biotech maximises market potential by providing prompt, efficient supply to its international clientele, reinforcing its status as a trusted exporter in the pharmaceutical domain.
FAQ's of 360 MG Mycophenolic Acid Delayed-Release Tablets USP:
Q: How should MOFOCON-S 360 tablets be taken for best results?
A: MOFOCON-S 360 tablets must be swallowed whole, not chewed or crushed, and administered exactly as directed by your physician to ensure optimal immunosuppressive effect.
Q: What is the main benefit of using the delayed-release form of Mycophenolic Acid?
A: The delayed-release formulation targets specific areas in the gastrointestinal tract, ensuring a steady release of the active ingredient for enhanced efficacy and reduced gastrointestinal side effects.
Q: When is MOFOCON-S 360 prescribed?
A: MOFOCON-S 360 is prescribed for the prevention of organ rejection in adult renal transplant patients as part of a comprehensive immunosuppressive regimen.
Q: Where is MOFOCON-S 360 manufactured and marketed?
A: MOFOCON-S 360 is both manufactured and marketed by Concord Biotech, an established pharmaceutical company based in India, ensuring quality and reliability.
Q: What is the recommended process for storing MOFOCON-S 360 tablets?
A: Store MOFOCON-S 360 below 25C in its original blister packaging to maintain stability and efficacy throughout its 24-month shelf life.
Q: Who can supply and export MOFOCON-S 360 tablets globally?
A: Authorised traders, suppliers, and exporters from India, represented by Concord Biotech, facilitate the global supply of MOFOCON-S 360 to meet international medical demands.